/PRNewswire/ HepaTx, a preclinical-stage biotechnology company developing cell therapies for liver diseases, announced today that Mazen Noureddin, MD, MHSc,.
HepaTx appoints Salah Kivlighn as new CEO
News provided by
Share this article
Share this article
PALO ALTO, Calif., April 15, 2021 /PRNewswire/ HepaTx Corporation, a preclinical stage company developing cell therapies for the treatment of liver disease, is pleased to announce the appointment of Salah Kivlighn, PhD as Chief Executive Office. An experienced business leader, Dr. Kivlighn will succeed Co-founder Eric Schuur, PhD and assume responsibilities on April 15
th, 2021.
Dr. Kivlighn brings a rare blend of science and business acumen to HepaTx. His experience spans therapeutic classes including oncology, vaccines, immuno-oncology, and cardiovascular disease treatments and multiple aspects of drug development and commercialization. His accomplishments include: guided the discovery, evolution, and commercialization of Losartan (Cozaar®), a market-leading antihypertensive drug becoming a $3.5B franchise (Merck & Co.); co-led the development and commercialization of RotaTeq
Share this article
Share this article
PALO ALTO, Calif., March 12, 2021 /PRNewswire/ HepaTx Corporation, Namocell Inc., and Takara Bio USA, Inc. (TBUSA) announced successful completion of the second phase of their collaboration on single cell analysis of hepatocyte-like cells (iHeps) differentiated from adipose tissue-derived stromal cells (ASCs) using Namocell s Single Cell Dispensers and Takara Bio s SMART-seq® kits to characterize HepaTx s novel cell therapies for liver disease. The results of the second phase demonstrated a 95% success rate in single cell isolation and library construction. Single cell RNA-seq showed distinct clusters of cells at various differentiation stages. The high reproducibility of results within sample groups will support development of novel cell therapies and validate production processes.